3-Octadec-9-enoyl-5-oxodocos-13-enoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-Octadec-9-enoyl-5-oxodocos-13-enoic acid
• 英文别名: 3-octadec-9-enoyl-5-oxodocos-13-enoic acid
• 化学式: C₄₀H₇₂O₄
• 分子量: 617.0
• InChiKey: PWWZRHOGQLBFPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14
• 重原子数：
  44
• 可旋转键数：
  35
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  71.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Emulation of lipoprotein structures
  申请人：Marina Biotech, Inc.

  公开号：EP2277508A1

  公开（公告）日：2011-01-26

  The invention concerns lipid assemblies, liposomes having an outer surface comprising a mixture of anionic and cationic moieties; wherein at least a portion of the cationic moieties are guanido groups, and their use for serum resistant transfection of cells.

  本发明涉及脂质组合物，脂质体的外表面包含阴离子和阳离子的混合物；其中阳离子至少有一部分是鸟苷酸基团，以及它们在细胞抗血清转染中的用途。
• Imino compounds for amphoteric liposomes and uses thereof
  申请人：NOVOSOM VERWALTUNGS GMBH

  公开号：US10039714B2

  公开（公告）日：2018-08-07

  The invention concerns lipid assemblies, liposomes having an outer surface comprising a mixture of anionic and cationic moieties; wherein at least a portion of the cationic moieties are imino moieties that are essentially charged under physiological conditions, and their use for serum resistant transfection of cells.

  本发明涉及脂质组合物，脂质体的外表面包含阴离子和阳离子的混合物；其中阳离子至少有一部分是亚氨基，在生理条件下基本上是带电的，本发明还涉及脂质体在细胞抗血清转染中的应用。
• AMPHOTERIC LIPOSOMES COMPRISING IMINO LIPIDS
  申请人：Marina Biotech, Inc.

  公开号：EP2451440A1

  公开（公告）日：2012-05-16
• Amphoteric liposomes comprising imino lipids
  申请人：Novosom Verwaltungs GmbH

  公开号：EP2823810B1

  公开（公告）日：2019-03-27
• AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS
  申请人：Panzner Steffen

  公开号：US20100330154A1

  公开（公告）日：2010-12-30

  An amphoteric liposome comprising neutral lipids wherein said neutral lipids are selected from the group comprising cholesterol or mixtures of cholesterol and at least one neutral or zwitterionic lipid and wherein K (neutral) of said mixtures is 0.3 or less. Said amphoteric liposome may encapsulate an active agent, such as nucleic acid therapeutics. Also disclosed are pharmaceutical compositions comprising said amphoteric liposomes as a carrier for the delivery or targeted delivery of active agents or ingredients.